Back to Results

Erasca Inc (ERAS)

Featured in Overvalued Stocks High-Beta Stocks High-Beta Momentum

Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for cancers driven by the RAS/MAPK pathway. Its pipeline includes ERAS-0015, a pan-RAS molecular glue for patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody for EGFR and RAS/MAPK solid tumors. The company also has collaboration and licensing arrangements with Guangzhou Joyo Pharmatech, Medshine Discovery, Novartis Pharma, NiKang Therapeutics, Asana BioSciences, and Tango Therapeutics covering selected programs and related development activities. Erasca was incorporated in 2018 and is headquartered in San Diego, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-ERAS
$15.84
-16.9% Downside
Fair
$22.80
19.6% Upside
Undervalued
Good
—
—
—
0.0%
August 6, 2026
-23.9x
16.8x
—
6.533 B
6.261 B
0.7%
79.6%
54.3
—
33.0%
Valuation • Fair Value

Erasca Inc (NASDAQ-ERAS) Fair Value by Valuation Model

Compare the primary fair value estimate for Erasca Inc (NASDAQ-ERAS) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$15.84

Estimated downside of 16.9% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$22.60

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$10.77

Comparable-company valuation reference.

Analyst Price Target

$22.80

Analysts imply upside of 19.6%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Erasca Inc (NASDAQ-ERAS) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Erasca Inc (NASDAQ-ERAS)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-130.7 M

Current operating profitability reference.

EBITDA Forecast

-312.9 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Erasca Inc (NASDAQ-ERAS) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Erasca Inc (NASDAQ-ERAS)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Good

Positive financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

54.3

Relatively strong balance-sheet zone.

FCF / Net Income

33.0%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Erasca Inc (NASDAQ-ERAS). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Erasca Inc (NASDAQ-ERAS)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 6, 2026

Days to Earnings

16

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Erasca Inc (NASDAQ-ERAS), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Erasca Inc (NASDAQ-ERAS) Stock Forecast & Technical Outlook

Review Erasca Inc (NASDAQ-ERAS) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Erasca Inc (NASDAQ-ERAS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Erasca Inc (NASDAQ-ERAS) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Buy

The daily technical read for Erasca Inc (NASDAQ-ERAS) is currently Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Buy

The weekly technical read for Erasca Inc (NASDAQ-ERAS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Erasca Inc (NASDAQ-ERAS) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Erasca Inc (NASDAQ-ERAS)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Erasca Inc (NASDAQ-ERAS) has a Strong Buy consensus, with 6 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 6
Hold 2
Sell 0
FAQ • Fast Investor Answers

Erasca Inc (NASDAQ-ERAS) Stock FAQ

Quick answers about Erasca Inc (NASDAQ-ERAS) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$15.84
Estimated downside 16.9%
Valuation Rating
Overvalued
Estimated downside of 16.9%
Analyst Target
$22.80
Implied upside 19.6%
Financial Health
Good
Current financial-health read

The current fair value estimate for Erasca Inc (NASDAQ-ERAS) is $15.84. This implies an estimated downside of 16.9% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 16.9% versus the current market price.

The available analyst price target for Erasca Inc (NASDAQ-ERAS) is $22.80. The analyst target implies estimated upside of 19.6%.

The current financial health read for Erasca Inc (NASDAQ-ERAS) is Good. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Erasca Inc (NASDAQ-ERAS) is August 6, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Erasca Inc (NASDAQ-ERAS) is -23.9x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Erasca Inc is 6.533 B.

The current enterprise value listed for Erasca Inc is 6.261 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Erasca Inc is NASDAQ-ERAS, and the stock is listed on NASDAQ.

Erasca Inc (NASDAQ-ERAS) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Erasca Inc is 0.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Erasca Inc is 79.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NASDAQ View more

Amgen Inc (AMGN) Amgen Inc (AMGN)
Gilead Sciences Inc (GILD) Gilead Sciences Inc (GILD)
Vertex Pharmaceuticals Inc (VRTX) Vertex Pharmaceuticals Inc (VRTX)
Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN)
Argenx NV ADR (ARGX) Argenx NV ADR (ARGX)
Revolution Medicines Inc (RVMD) Revolution Medicines Inc (RVMD)
Natera Inc (NTRA) Natera Inc (NTRA)
Alnylam Pharmaceuticals Inc (ALNY) Alnylam Pharmaceuticals Inc (ALNY)
BeOne Medicines AG DRC (ONC) BeOne Medicines AG DRC (ONC)
Biogen Inc (BIIB) Biogen Inc (BIIB)
Roivant Sciences Ltd (ROIV) Roivant Sciences Ltd (ROIV)
Moderna Inc (MRNA) Moderna Inc (MRNA)
BioNTech SE (BNTX) BioNTech SE (BNTX)
Insmed Inc (INSM) Insmed Inc (INSM)
Incyte Corporation (INCY) Incyte Corporation (INCY)
United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR)
Neurocrine Biosciences Inc (NBIX) Neurocrine Biosciences Inc (NBIX)
Genmab AS (GMAB) Genmab AS (GMAB)
BridgeBio Pharma Inc (BBIO) BridgeBio Pharma Inc (BBIO)
Ascendis Pharma AS (ASND) Ascendis Pharma AS (ASND)
Exelixis Inc (EXEL) Exelixis Inc (EXEL)
Madrigal Pharmaceuticals Inc (MDGL) Madrigal Pharmaceuticals Inc (MDGL)
Abivax SA ADR (ABVX) Abivax SA ADR (ABVX)
Biomarin Pharmaceutical Inc (BMRN) Biomarin Pharmaceutical Inc (BMRN)